DOI: https://dx.doi.org/10.18565/pharmateca.2024.10.55-62
Курдина М.И., Коленько Н.Г.
1) АО «Медси 2», Москва, Россия; 2) АО «Медси 2», Москва, Россия; 3) Российский университет дружбы народов им. Патриса Лумумбы, Москва, Россия
1. Farley E., Masrour S., McKey J., Menter A. Palmoplantar psoriasis: a phenotypical and clinical review with introduction of a new quality-of-life assessment tool. J Am Acad Dermatol. 2009;60(6):1024–1031. DOI: 10.1016/j.jaad.2008.11.910. 2. Chung J., Callis Duffin K., Takeshita J., et al. Palmoplantar psoriasis is associated with greater impairment of health-related quality of life compared to moderate-to-severe plaque psoriasis. J Am Acad Dermatol. 2014;71(4):623–632. DOI: 10.1016/j.jaad.2014.04.063. 3. Merola J.F., Li T., Li W.Q., et al. Prevalence of psoriasis phenotypes among men and women in the USA. Clin Experimental Dermatol. 2016;41(5):486–489. DOI: 10.1111/ced.12805. 4. Dopytalska K., Sobolewski P., Biaszczak A., et al. Psoriasis in special localizations. Reumatologia. 2018;56(6):392–398. DOI: 10.5114/reum.2018.80718. 5. Horner M.E., Orroth K.K., Ma J., et al. Redefining Disease Severity with Special Area Involvement and Reflecting on Treatment Patterns in a Real-World Psoriasis Population. Dermatol Ther (Heidelb). 2024;14(1):187–199. DOI: 10.1007/s13555-023-01065-0. 6. Engin B., Askın O., Tüzün Y. Palmoplantar psoriasis. Clin Dermatol. 2017;35(1):19–27. DOI: 10.1016/j.clindermatol.2016.09.004. 7. Timotijevic Z.S., Trajkovic G., Jankovic J., et al. How frequently does palmoplantar psoriasis affect the palms and/or soles? Postepy Dermatol Alergol. 2019;36(5):595–603. DOI: 10.5114/ada.2019.89508. 8. Navarini A.A., Burden A.D., Capon F., et al.; ERASPEN Network. European consensus statement on phenotypes of pustular psoriasis. J Eur Acad Dermatol Venereol. 2017;31(11):1792–1799. DOI: 10.1111/jdv.14386. 9. Bachelez H. Pustular Psoriasis: The Dawn of a New Era. Acta Derm Venereol. 2020;100(3):5651. DOI: 10.2340/00015555-3388. 10. Yamamoto T. Similarity and difference between palmoplantar pustulosis and pustular psoriasis. J Dermatol. 2021;48(6):750–760. DOI: 10.1111/1346-8138.15826. 11. Raposo I., Torres T. Palmoplantar psoriasis and palmoplantar pustulosis: current treatment and future prospects. Am J Clin Dermatol. 2016;17(4):349–358. DOI: 10.1007/s40257-016-0191-7. 12. Лихонос Л.М., Смирнова И.О. Ладонно-подошвенный пустулез: патогенетические, клинические и эпидемиологические особенности. Клиническая дерматология и венерология. 2017;3:4-12. 13. Wilsmann-Theis D., Jacobi A., Frambach Y., et al. Palmoplantar pustulosis – a cross-sectional analysis in Germany. Dermatol Online J. 2017;23(4):13030/qt0h15613d. 14. Miceli A., Schmieder G.J. Palmoplantar Psoriasis. 2023 Aug 8. In: StatPearls 15. Trattner H., Bluml S., Steiner I., et al. Quality of life and comorbidities in palmoplantar pustulosis – a cross-sectional study on 102 patients. J Eur Acad Dermatol Venereol. 2017;31(10):1681–1685. DOI: 10.1111/jdv.14187. 16. Naik H.B., Cowen E.W. Autoinflammatory pustular neutrophilic diseases. Dermatol Clin. 2013;31(3):405–425. DOI: 10.1016/j.det.2013.04.001. 17. Chularojanamontri L., Rattanakorn K., Julanon N., et al. Acrodermatitis continua of Hallopeau and generalised pustular psoriasis: Should they be the same or different entities? Exp Dermatol. 2023;32(8):1235–1245. DOI: 10.1111/exd.14805. 18. Coates L.C., Kavanaugh A., Mease P., et al. Group for Research and Assessment of Psoriasis and Psoriatic Arthritis 2015 Treatment Recommendations for Psoriatic Arthritis. Arthritis Rheumatol. 2016;68(5):1060–1071. DOI: 10.1002/art.39573. 19. Puig L., Bakulev A.L., Kokhan M.M. et al. Efficacy and Safety of Netakimab, A Novel Anti-IL-17 Monoclonal Antibody, in Patients with Moderate to Severe Plaque Psoriasis. Results of A 54-Week Randomized Double-Blind Placebo-Controlled PLANETA Clinical TrialDermatol Ther (Heidelb). 2021;11(4):1319–1332. DOI: 10.1007/s13555-021-00554-4. 20. Au S.C., Goldminz A.M., Kim N., et al. Investigator-initiated, open-label trial of ustekinumab for the treatment of moderate-to-severe palmoplantar psoriasis. J Dermatolog Treat. 2013;24(3):179–187. DOI: 10.3109/09546634.2012.672710. 21. Gelfand J.M., Wan J., Callis Duffin K., et al. Comparative effectiveness of commonly used systemic treatments or phototherapy for moderate to severe plaque psoriasis in the clinical practice setting. Arch Dermatol. 2012;148(4):487–494. DOI: 10.1001/archdermatol.2012.370. 22. Takahashi H., Iinuma S., Tsuji H., et al. Biologics are more potent than other treatment modalities for improvement of quality of life in psoriasis patients. J Dermatol. 2014;41(8):686–689. DOI: 10.1111/1346-8138.12544. 23. Hueber W., Patel D.D., Dryja T. et al.; Psoriasis Study Group; Rheumatoid Arthritis Study Group; Uveitis Study Group. Effects of AIN457, a fully human antibody to interleukin-17A, on psoriasis, rheumatoid arthritis, and uveitis. Sci Transl Med. 2010;2(52):52ra72. DOI: 10.1126/scitranslmed.3001107. 24. Ivanov S., Linden A. Interleukin-17 as a drug target in human disease. Trends Pharmacol Sci. 2009;30:95–103. DOI: 10.1016/j.tips.2008.11.004. 25. Хотко А.А., Круглова Л.С., Помазанова М.Ю., Хотко Р.А. Эффективность препарата нетакимаб в реальной клинической практике у пациентов с тяжелыми формами псориаза Медицинский алфавит. 2020;(6):28–33. 26. Кубанов А.А., Карамова А.Э., Притуло О.А. и др. Псориаз: клинические рекомендации. М., 2023. 78 с. 27. Bhushan M., Burden A.D., McElhone K., et al. Oral liarozole in the treatment of palmoplantar pustular psoriasis: a randomized, double-blind, placebo-controlled study. Br J Dermatol. 2001;145(4):546–553. DOI: 10.1046/j.1365-2133.2001.04411.x. 28. Tsiogkas S.G., Grammatikopoulou M.G., Kontouli K.M., et al. Efficacy of biologic agents for palmoplantar psoriasis: a systematic review and network meta-analysis. Expert Rev Clin Immunol. 2023;19(12):1485–1498. DOI: 10.1080/1744666X.2023.2272049. 29. Zhang L., Su Y., Shucheng H., et al. Systemic therapy in treating palmoplantar and scalp psoriasis: A systematic review and network meta-analysis. JAAD. 2024;90(3):646–648. DOI: 10.1016/j.jaad.2023.10.064. 30. Galluzzo M., Talamonti M., Atzori L., et al. Secukinumab for the treatment of palmoplantar psoriasis: a 2-year, multicenter, real-life observational study. Expert Opin Biol Ther. 2022;22(4):547–554. DOI: 10.1080/14712598.2022.2029841. 31. Leonardi C., Langley R.G., Papp K., et al. Adalimumab for treatment of moderate to severe chronic plaque psoriasis of the hands and feet: efficacy and safety results from REACH, a randomized, placebo-controlled, double-blind trial. Arch Dermatol. 2011 Apr;147(4):429–436. DOI: 10.1001/archdermatol.2010.384. 32. Bissonnette R., Poulin Y., Guenther L., et al. Treatment of palmoplantar psoriasis with infliximab: a randomized, double-blind placebo-controlled study. J Eur Acad Dermatol Venereol. 2011;25(12):1402–1408. DOI: 10.1111/j.1468-3083.2011.03984.x. 33. Au S.C., Madani A., Alhaddad M., et al. Comparison of the efficacy of biologics versus conventional systemic therapies in the treatment of psoriasis at a comprehensive psoriasis care center. J Drugs Dermatol. 2013;12(8):861–866. DOI: 10.1016/j.jaad.2012.12.808. 34. Terui T., Kobayashi S., Okubo Y., et al. Efficacy and Safety of Guselkumab, an Anti–interleukin 23 Monoclonal Antibody, for Palmoplantar Pustulosis. JAMA Dermatol. 2018;154(3):309–316. DOI: 10.1001/jamadermatol.2017.5937. 35. Caldarola G., Zangrilli A., Palmisano G., et al. Effectiveness of risankizumab in the treatment of palmoplantar psoriasis: a 52-week Italian real-life experience. Drugs Context. 2023;12:2023–1–8. DOI: 10.7573/dic.2023-1-8.
Автор для связи: Мария Игоревна Курдина, д.м.н., профессор, главный специалист по дерматовенерологии и косметологии, АО «МЕДСИ 2», Москва, Россия; m.i.kurdina@gmail.com ORCID
М.И. Курдина (Maria I. Kurdina), https://orcid.org/0009-0006-5963-4763
Н.Г. Коленько (Natalia G. Kolenko), https://orcid.org/0000-0002-9090-8287